Sydney, Australia – LTR Pharma Limited (ASX:LTP), an ASX listed clinical stage pharmaceutical company, is excited to announce the successful commencement of its pivotal clinical study for SPONTAN®, a novel nasal spray aimed at treating erectile dysfunction (ED). This marks a significant milestone in the company's mission to revolutionize the treatment landscape for men experiencing ED.
The study has begun with the first patients receiving doses of SPONTAN®, which utilizes a unique nasal delivery technology. This innovative approach is designed to rapidly deliver medication, ensuring a faster onset compared to traditional methods. The clinical trial aims to recruit 18 participants and is being conducted at a single site, focusing on the bioequivalence of SPONTAN® compared to Vardenafil, a widely used oral PDE5 inhibitor.
Erectile dysfunction is a prevalent condition that can significantly impact a person's quality of life, affecting not only physical health but also contributing to mental health issues and relationship strains. SPONTAN® represents a breakthrough in ED treatment, offering a discreet and efficient alternative to oral medications.
LTR Pharma Chairman, Lee Rodne, expressed his enthusiasm about the study's progress: "The Study is off to a great start, and we are grateful to the participants interested in entering the study. SPONTAN nasal spray represents a potential paradigm shift in the treatment for erectile dysfunction and is a promising disruptor to the global blockbuster PDE5 market, offering a discreet and efficient treatment alternative. We are excited to bring this key innovation to men worldwide.”
LTR Pharma is dedicated to improving men's health by developing and commercializing innovative treatments. The company's focus on SPONTAN® underscores its commitment to providing effective solutions for conditions like ED that affect millions of men around the globe.
About us:
LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.
Contact details:
Jane Morgan
jm@janemorganmanagement.com.au